How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,005 results for

Androgenic Alopecia

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

321. Forxiga - dapagliflozin

(comparators were metformin XR and glipizide) in drug-naïve subjects at an early stage of disease and subjects who require additional therapy after failure to reach adequate glycaemic control with their current regimen, including oral anti-diabetic agents or insulin at a later stage of the disease. The clinical development program also examined the persistent loss of calories in the urine due to glucosuria and the resulting potential for weight loss with a reduction in total body fat. The clinical studies (...) at lower doses. This study also demonstrated the reversibility of dapagliflozin’s action towards SGLT2. As in healthy animals, dapagliflozin led to increased renal glucose excretion and urine flow in ZDF rats. However, this renal glucose loss also led to a counter-regulatory endogenous glucose production and increased nutrient (i.e. food) intake. The advantage of these counter-regulatory mechanisms was that dapagliflozin decreased the blood glucose level but did not cause hypoglycaemia. The renal

2012 European Medicines Agency - EPARs

322. Signifor - pasireotide

microadenomas ( = 1 cm in diameter); macroadenomas are rare. The elevated levels of ACTH secreted by these tumours stimulate the adrenal glands to produce excess cortisol, thereby leading to the subsequent development of the clinical signs and symptoms of hypercortisolism. In patients with Cushing’s disease, most adenomatous cells develop a high set-point for feedback inhibition of ACTH secretion by cortisol, which may lead to loss of tumour differentiation to the point where increased cortisol levels can (...) are summarised. Ketoconazole is an anti-fungal agent that inhibits the synthesis of cortisol, adrenal and gonadal androgens. It is an 11 ß-hydroxylase and 17 a-hydroxylase inhibitor, which leads to a decrease in cortisol production. Published studies on the use of ketoconazole in Cushing’s syndrome are small and/or retrospective. The initial efficacy with ketoconazole (normalization of UFC) is up to 81% of patients with Cushing’s disease, but escape is possible requiring continued dose escalation

2012 European Medicines Agency - EPARs

323. Post-menopausal Hormone Treatment Update (DOPS, KEEPS)

for biliary tract surgery in postmenopausal women with coronary artery disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2001 Oct 2;135(7):493-501. 42 Cauley JA, Black DM, Barrett-Connor E, Harris F, et al. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med. 2001 Apr 15;110(6):442-50. 43 Chelebowski R, Hendrix S, Langer R, Stefanick M, et al. Influence of Estrogen Plus Progestin (...) -analysis of Randomized Controlled Trials. Arch Intern Med. 2006 Jun 26;166(12):1256-61. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309-18. Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. 2005 Aug

2012 RxFiles

324. Naturally Occurring Hair Growth Peptide: Water-Soluble Chicken Egg Yolk Peptides Stimulate Hair Growth Through Induction of Vascular Endothelial Growth Factor Production. (Abstract)

Naturally Occurring Hair Growth Peptide: Water-Soluble Chicken Egg Yolk Peptides Stimulate Hair Growth Through Induction of Vascular Endothelial Growth Factor Production. Alopecia is divided into two categories: androgenic alopecia and nonandrogenic alopecia. An androgen-dependent abnormality of biological functions causes alopecia in males, but the role of androgens is not yet elucidated in female pattern hair loss (FPHL). Modulation of androgenic activity is not effective in certain kinds (...) of androgenic alopecia in females, as well as in cases of nonandrogenic alopecia in males and females. The hair growth drug, minoxidil, stimulates vascular endothelial growth factor (VEGF) production as well as vascularization and hair growth in females. Yet, because minoxidil has side effects with long-term use, a safe alternative hair growth agent is needed. Whereas hair develops after birth in mammalian species, hair mostly grows in a precocial bird, in the chicken, between hatching days 14 and 15

2018 Journal of medicinal food Controlled trial quality: uncertain

325. Sesquiterpene-Enriched Extract of Curcuma aeruginosa Roxb. Retards Axillary Hair Growth: A Randomised, Placebo-Controlled, Double-Blind Study. (Abstract)

Sesquiterpene-Enriched Extract of Curcuma aeruginosa Roxb. Retards Axillary Hair Growth: A Randomised, Placebo-Controlled, Double-Blind Study. Sesquiterpenes in Curcuma aeruginosa Roxb. inhibit steroid 5α-reductase and dihydrotestosterone production, and reverse androgenic alopecia. This study sought to show that a high sesquiterpene C. aeruginosa extract (CA-ext) retards axillary hair growth in women.Thirty women (age 20-52 years) were recruited into a 12-week, double-blind, placebo-controlled (...) , the preparation was well accepted and matched the effectiveness of finasteride. Thus, with some refinement, it should provide an alternative pharmacological treatment for unwanted androgenic hair.© 2018 S. Karger AG, Basel.

2018 Skin pharmacology and physiology Controlled trial quality: predicted high

326. Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

resistance increases angiogenesis and metastasis, leading to disease progression Targeting the hypoxia driven tumor microenvironment (e.g. down-regulation of HIF-1Alpha) in addition to the androgen receptor (e.g. enzalutamide) has synergistic activity against prostate cancer cell line models (e.g. LNCaP, 22Rv1). CRLX101 is a nanoparticle drug conjugate composed of 20(S)-camptothecin (a potent and highly selective topoisomerase I inhibitor with anti-HIF-1Alpha properties) conjugated to a linear (...) levels above institutional normal. Patients must have castrate levels of testosterone (<50 ng/dL [1.74 nmol/L]). Patients must have undergone bilateral surgical castration or must continue on GnRH agonists/antagonists for the duration of the study. Patients on 5-alpha reductase inhibitors such as finasteride or dutasteride must stop medication at least 28 days prior to study entry. The effects of enzalutamide and CRLX101 on the developing human fetus are unknown. For this reason and because androgen

2018 Clinical Trials

327. To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin

therapy History of active hair loss due to alopecia areata, scarring alopecia, diffuse telogen effluvium or conditions other than androgenetic alopecia Immunological disorders such as alopecia areata, and systemic lupus erythematosus and other systemic known autoimmune disorders Diabetes mellitus Coagulation deficiencies Topical treatments for hair growth (minoxidil, anti-androgens or other agents known to affect hair growth) in the last 6 months Topical treatments of the scalp including (...) Phase Androgenic Alopecia Drug: FOL-005 Drug: Placebo Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 60 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Randomised, Double-blind, Placebo-controlled Phase 2 Trial of FOL-005 to Investigate Efficacy on Hair Growth on Scalp

2018 Clinical Trials

328. Testosterone Enanthate and Olaparib in Treating Participants With Castration-Resistant Prostate Cancer

Cypionate Phase 2 Detailed Description: PRIMARY OBJECTIVES: I. Determine the prostate-specific antigen (PSA)50 response rate (i.e., percent of patients with a PSA decline of at least 50% below baseline) following 12-weeks of treatment with bipolar androgen therapy (BAT) (i.e., intermittent high dose testosterone) plus olaparib in men with asymptomatic metastatic castration-resistant prostate cancer (mCRPC) who have progressed on abiraterone and/or enzalutamide. SECONDARY OBJECTIVES: I. Determine (...) information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 30 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Bipolar Androgen Therapy Plus Olaparib in Patient With Castration-Resistant Prostate Cancer Actual Study Start Date : August 29, 2018 Estimated Primary Completion Date : March 1, 2021 Estimated Study Completion Date : March 1, 2023 Resource links provided by the National Library of Medicine related

2018 Clinical Trials

329. 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

of separate clinical protocol are eligible (must meet all study eligibility criteria) Documented disease progression on or after prior systemic treatment administered for the advanced disease including CYP 17 inhibitors and/or androgen-pathway inhibitors (i.e. abiraterone and/or enzalutamide when available) and no more than one line of chemotherapy for the advanced disease, or patients who were ineligible (unfit) to receive chemotherapy. Disease progression defined as increasing serum PSA (per PCWG3 (...) ), radiological progression or ≥ 2 new bone lesions. (Chemical castration is required unless surgically orchiectomized.) At least 28 days elapsed between last anti-cancer treatment administration and the initiation of study treatment (except for Luteinizing Hormone-releasing Hormone [LHRH] or Gonadotropin-releasing Hormone [GnRH]), or resolution of all previous treatment related toxicities to CTCAE version 4.03 grade of ≤ 1 (except for chemotherapy induced alopecia and grade 2 peripheral neuropathy or grade 2

2018 Clinical Trials

330. Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

prostate cancer that has spread to other places in the body. Androgen can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, may lessen the amount of androgen made by the body. Decitabine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving decitabine and enzalutamide may work better in treating participants with castration resistant prostate cancer. Condition or disease Intervention/treatment Phase Castration Levels of Testosterone (...) ] Will calculate the mean and standard deviation for these markers. LINE-1 methylation levels assessed in peripheral blood by pyrosequencing (Phase II) [ Time Frame: Up to 24 months ] Will calculate the mean and standard deviation for these markers. Number of circulating tumor cells (CTCs) and proportion of stem/progenitor cells in CTC population (Phase II) [ Time Frame: Up to 24 months ] Will calculate the mean and standard deviation for these markers. Presence or emergence of androgen receptor (AR) mutations

2018 Clinical Trials

331. First Time in Humans (FTIH) Study of GSK3368715 in Subjects With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)

is longer, up to a maximum wash-out period of 28 days prior to initiation of study drug administration. Anti-androgen therapies for prostate cancer, such as bicalutamide, must be stopped 28 days prior to first dose of GSK3368715. Second-line hormone therapies such as enzalutamide or abiraterone should be stopped 14 days prior to enrolment. Subjects with prostate cancer may remain on luteinizing hormone-releasing hormone (LHRH) agonists or antagonists and/or low-dose prednisone or prednisolone (up to 10 (...) milligrams per day [mg/day]). Nitrosureas and mitomycin C must be stopped within 42 days prior to first dose of GSK3368715. Allogeneic hematopoietic stem-cell transplantation. Toxicities from previous anti-cancer therapies have not resolved to Baseline or National Cancer Institute (NCI) CTCAE V4.0. <=Grade 1 (except fatigue and alopecia [permissible at any grade] and peripheral neuropathy [which must be <= Grade 2]) at the time of starting study intervention. Radiotherapy within 14 days before

2018 Clinical Trials

332. A Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)

or cytologically confirmed (by clinical site) adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features. Ongoing androgen deprivation therapy with a GnRH analog or bilateral orchiectomy (surgical or medical castration). Serum testosterone ≤1.73 nmol/L (50 ng/dL) at screening. PSA progression on treatment with abiraterone and/or enzalutamide and/or apalutamide. PSA progression is defined by a minimum of 2 rising PSA levels with an interval of ≥1 week between each determination (...) resolved to Grade ≤1 before the start of study therapy (with the exception of alopecia [Grade 1 or 2 permitted], neurotoxicity [Grade 1 or 2 permitted], or bone marrow parameters [Grade 1 or 2 permitted with exceptions as noted below]). Adequate bone marrow function: Absolute neutrophil count (ANC) ≥1.0 x 109/L Platelet count ≥75 x 109/L Hemoglobin ≥80 g/L (8.0 g/dL or 4.9 mmol/L) Adequate hepatic function: Serum alanine aminotransferase (ALT) ≤3 x upper limit of normal (ULN), ≤ 5 x ULN in the presence

2018 Clinical Trials

333. Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

. If a patient declines to participate in the optional exploratory genetic research or the optional biomarker research, there will be no penalty or loss of benefit to the patient. The patient will not be excluded from other aspects of the study. Patients must be ≥18 years of age (or ≥19 years of age in South Korea) at the time of signing the informed consent form. For patients enrolled in Japan who are <20 years of age, written informed consent should be obtained from the patient and from his legally (...) acceptable representative. Histologically or cytologically confirmed prostate adenocarcinoma. Metastatic status defined as at least 1 documented metastatic lesion on either a bone scan or a computed tomography(CT)/ magnetic resonance imaging (MRI) scan. First-line metastatic castration-resistant prostate cancer (mCRPC). Ongoing androgen deprivation with gonadotropin-releasing hormone analogue or bilateral orchiectomy, with serum testosterone <50 nanograms per decilitre (ng/dL) (<2.0 nanomoles per litre

2018 Clinical Trials

334. Hair-Growth Potential of Ginseng and Its Major Metabolites: A Review on Its Molecular Mechanisms Full Text available with Trip Pro

. A variety of factors, such as hormones, nutritional status, and exposure to radiations, environmental toxicants, and medications, may affect hair growth. Androgens are the most important of these factors that cause androgenic alopecia. Other forms of hair loss include immunogenic hair loss, that is, alopecia areata. Although a number of therapies, such as finasteride and minoxidil, are approved medications, and a few others (e.g., tofacitinib) are in progress, a wide variety of structurally diverse (...) Hair-Growth Potential of Ginseng and Its Major Metabolites: A Review on Its Molecular Mechanisms The functional aspect of scalp hair is not only to protect from solar radiation and heat/cold exposure but also to contribute to one's appearance and personality. Progressive hair loss has a cosmetic and social impact. Hair undergoes three stages of hair cycle: the anagen, catagen, and telogen phases. Through cyclical loss and new-hair growth, the number of hairs remains relatively constant

2018 International journal of molecular sciences

335. Therapeutic Potential of Stem Cells in Follicle Regeneration Full Text available with Trip Pro

an encouragement to seek new, more effective therapies aimed at hair follicle regeneration and neoregeneration. We know that stem cells can be used to regenerate hair in several therapeutic strategies: reversing the pathological mechanisms which contribute to hair loss, regeneration of complete hair follicles from their parts, and neogenesis of hair follicles from a stem cell culture with isolated cells or tissue engineering. Hair transplant has become a conventional treatment technique in androgenic alopecia (...) Therapeutic Potential of Stem Cells in Follicle Regeneration Alopecia is caused by a variety of factors which affect the hair cycle and decrease stem cell activity and hair follicle regeneration capability. This process causes lower self-acceptance, which may result in depression and anxiety. However, an early onset of androgenic alopecia is associated with an increased incidence of the metabolic syndrome and an increased risk of the cardiac ischaemic disease. The ubiquity of alopecia provides

2018 Stem Cells International

336. Metabolic syndrome and the skin: a more than superficial association. Reviewing the association between skin diseases and metabolic syndrome and a clinical decision algorithm for high risk patients Full Text available with Trip Pro

is to present plausible mechanistic connections. The severity of skin conditions like psoriasis has been linked with MeTS. Parameters of MeTS like insulin resistance are present in patients with early onset androgenic alopecia, hidradenitis suppurativa acne and rosacea. Since MeTS can lead to CVD and type 2 diabetes early detection of patients would be very important. Also therapeutic intervention on MeTS could lead to improvement on the severity of skin conditions. This reciprocal relationship between skin

2018 Diabetology & metabolic syndrome

337. Research Brief: Self-Reports of a Constellation of Persistent Antiandrogenic, Estrogenic, Physical, and Psychological Effects of Finasteride Usage Among Men Full Text available with Trip Pro

. Finasteride inhibits the conversion of testosterone (T) to dihydrotestosterone (DHT), and is commonly used to treat benign prostatic hypertrophy (BPH) and male pattern baldness (MPB), both disorders associated with elevated DHT levels and 5α-reductase activity in the prostate and hair follicles, respectively. It is now acknowledged that long-term use and discontinuation of finasteride has adverse effects (AEs); however, these claims have not been well documented. In this study, discussion board posts (...) Research Brief: Self-Reports of a Constellation of Persistent Antiandrogenic, Estrogenic, Physical, and Psychological Effects of Finasteride Usage Among Men Our research objective is to understand more, through subjective, self-reports on discussion boards/forums, persons' experiences associated with the use of drugs that alter androgen metabolism, such as finasteride. Finasteride is an orally active, specific inhibitor of 5α-reductase, which is localized to many androgen-dependent tissues

2018 American journal of men's health

338. Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

the use of chemotherapy in metastatic disease, while improving efficacy and durability of response. The approach combines two potentially effective and previously studied strategies: androgen receptor blockade and immune checkpoint therapy. Condition or disease Intervention/treatment Phase Breast Neoplasm Female Breast Cancer Breast Carcinoma Breast Tumor Drug: Nivolumab Drug: Ipilimumab Drug: Bicalutamide Phase 2 Detailed Description: This is a phase II trial to assess the clinical efficacy (...) and safety of nivolumab (anti-Programmed Death receptor-1, or anti-PD-1) combined with bicalutamide (Androgen Receptor (AR) inhibitor) and ipilimumab (anti-cytotoxic T-lymphocyte-associated protein 4, or anit-CTLA4) in patients with advanced breast cancer. This study will include adult women with metastatic or locally advanced unresectable Human Epidermal Growth Factor (HER2)-negative breast cancer (by National Comprehensive Cancer Network (NCCN) criteria). Triple-negative breast cancer tumors

2018 Clinical Trials

339. Ribociclib and Letrozole Treatment in Ovarian Cancer

(MONALEESA-2). Additional marketing authorizations are under review by health authorities. Additional phase III clinical trials for the treatment of hormone receptor positive (HR+) breast cancer patients, as well as several other phase I or II clinical studies are being conducted. Letrozole is a highly potent, orally active non-steroidal competitive inhibitor of the aromatase enzyme system. It effectively inhibits the conversion of androgens to estrogens both in vitro and in vivo. It is indicated both (...) injections (e.g., intra-articular) Patient who has received radiotherapy ≤4 weeks or limited field radiation for palliation ≤2 weeks prior to starting study drug, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom ≥25% of the bone marrow (Ellis, 1961) was irradiated. Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered

2018 Clinical Trials

340. Effects of VitaBeard® on Facial Hair Growth in Healthy Adult Men

with the performance of the study assessments Very little contrast between hair color and scalp (e.g., fair-haired with an extremely pale skin color) Use of any weight-loss programs or weight-loss medications (prescription or over-the counter) including, but not limited to, lipase inhibitors, within 6 months prior to visit 1 and throughout the study Individuals with an outdoor occupation (e.g. landscaper, surveyor, outdoor construction, etc.) Active skin diseases (e.g. eczema, atopic dermatitis, psoriasis, skin (...) Effects of VitaBeard® on Facial Hair Growth in Healthy Adult Men Effects of VitaBeard® on Facial Hair Growth in Healthy Adult Men - Full Text View - Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effects of VitaBeard®

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>